If cardiac function assessment is clinically indicated or performed: participants will be ineligible if left ventricular ejection fraction (LVEF) is less than normal per institutional guidelines, or < 55%, if the threshold for normal is not otherwise specified by institutional guidelines
Left ventricular (LV) ejection fraction <50%, evaluation based on the institutional lower limit of normal.
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO); ECHO scans must be used throughout the study when indicated
Left ventricular ejection fraction (LVEF) less than the lower limit of normal (LLN) as assessed by echocardiography
Baseline left ventricular ejection fraction (LVEF) below the lower limit of normal (LLN) or < 55% measured by echocardiography or institutionâ€™s lower limit of normal (LLN) for MUGA
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) (per institutional normal) determined by echocardiogram or nuclear medicine scan, within 30 days of registration
Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or <50%, whichever is lower Infections Patients who meet any of the following infection exclusion criteria will be excluded from study entry:
Adequate cardiac function as assessed by cardiac troponin I within normal range; left ventricular ejection fraction ? 50% or institutional lower limit of normal; cumulative anthracycline dose <360 mg/m2 doxorubicin or equivalent.
Left ventricular ejection fraction (LVEF) greater than (>) 50 percent (%) or above the lower limit of the institutional normal range, whichever is lower
INCLUSION CRITERIA FOR REGISTRATION (HER2 MUTATION IDENTIFIED BY WASH U GPS LABORATORY): Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN) within 4 weeks of registration
Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or below 50% Central Nervous System (CNS) Exclusion Criteria:
Ejection fraction < 55% or less than the lower limit of normal of the institutional standard.
Abnormal left ventricular ejection fraction (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower).
Left ventricular ejection fraction (LVEF) ?55% (or the institutional lower limit of normal [LLN]) as evidenced on ECHO.
Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or below 50 percent (%), whichever is lower General Exclusion Criteria
Left ventricular ejection fraction (LVEF) (echocardiogram [echo]) >= lower limit of normal (LLN).
STRATUM B: Participants with abnormal left ventricular ejection fraction (LVEF) on screening, defined as > 10% below lower limit of normal
Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or <50%, whichever is lower
Left ventricular ejection fraction < 50% or institutional lower limit of normal, whichever is lower
Abnormal left ventricular ejection fraction on echocardiography or MUGA (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower).
Left ventricular ejection fraction (LVEF) >= lower limit of institutional normal as assessed by echocardiography
Left ventricular ejection fraction (LVEF) < institutional lower limit of normal or < 50%
Left Ventricular Ejection Fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)
FULL STUDY INCLUSION CRITERIA: Left ventricular ejection fraction (LVEF) >= 50% or the lower limit of normal (LLN) according to local institution ranges of normality
Any of the following:\r\n* Correct QT (QTc) prolongation (defined as a QTc interval >= 500 msecs)\r\n* Left ventricular ejection fraction (LVEF) < institutional lower limits of normal (LLN)\r\n* Frequent ventricular ectopy\r\n* Evidence of ongoing myocardial ischemia
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) (institutional limit)
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN)
Abnormal left ventricular ejection fraction on echocardiography (less than the lower limit of normal for a patient of that age at the treating institution or < 45%)
Left ventricular ejection fraction at or above institutional lower limits of normal (by echocardiogram within 12 weeks of registration)
Congestive heart failure (NYHA class III or IV) within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal, per local institutional standards, within 6 months prior to enrollment
Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution's lower limit of predicted normal.
Left ventricular >= institutional lower limit of normal (LLN) by echocardiogram (ECHO) ejection fraction
Left ventricular ejection fraction (LVEF) ? 50% of the lower limit of normal (LLN) according to local institutional ranges
Ejection fraction below the lower limit of normal (< 50%)
Left ventricular ejection fraction (LVEF) equal to or above the lower limit of normal (LLN) at the institution.
Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower Phase Ib Dose-Escalation Arm B (Venetoclax and Idasanutlin): Received the following within 7 days prior to the initiation of study treatment:
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
Left ventricular ejection fraction below the lower limit of normal
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO), within 2 weeks of the first dose of study treatment
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
Left ventricular ejection fraction (LVEF) equal to or greater than the institutional lower limit of normal. LVEF must be evaluated within 28 days prior to beginning study therapy.
ECHO/MUGA demonstrating left ventricular ejection fraction (LVEF)? the lower limit of institutional normal
Left ventricular ejection fraction (LVEF) ? 50% or the lower limit of normal (LLN) according to local institution ranges of normality.
have major abnormalities documented by echocardiography (ECHO) with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction <50%, evaluation based on the institutional lower limit of normal). For additional details, refer to ECHO protocol.
If cardiac function assessment is clinically indicated or performed: participants will be ineligible if left ventricular ejection fraction (LVEF) is less than normal per institutional guidelines, or < 55%, if the threshold for normal is not otherwise specified by institutional guidelines
Left ventricular ejection fraction (LVEF) as assessed by baseline echocardiogram at or above the lower limit of normal
Left ventricular ejection fraction >= institutional lower limit of normal (LLN) by echocardiogram (ECHO)
Left ventricular ejection fraction by echocardiogram (ECHO) >= institutional lower limit of normal
Left ventricular ejection fraction (LVEF) ? lower limit of normal (LLN) for the Institution
Cardiac ejection fraction <LLN (lower limit of normal)
Cardiac left ventricular function with resting ejection fraction of less than institutional lower limit of normal.
Left ventricular ejection fraction (LVEF) < institutional lower limit of normal (LLN) by ECHO (preferred) or MUGA scan at the time of transition to this study.
Left ventricular ejection fraction (LVEF) </= institutional lower limit of normal (LLN) by ECHO at the time of transition to this study
Left ventricular ejection fraction (LVEF) >= lower limit of normal (LLN) by echocardiogram (ECHO)
Left ventricular ejection fraction of >= 55% (or institutional lower normal value)
Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection fraction (LVEF) below the institution's lower limit of predicted normal.
The patient has a baseline corrected QT interval (QTc) >480 ms or left ventricular ejection fraction (LVEF) <50% or less than the lower limit of normal.
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal (LLN)
Impaired cardiac function defined as left ventricular ejection fraction (LVEF) < 50 % (or below the study site's lower limit of normal) as measured by MUGA or ECHO.
Adequate cardiac function defined as: left ventricular ejection fraction (LVEF) of either >=50% by ECHO or greater than institutional lower limit of normal (LLN) by echocardiogram (ECHO) (while not receiving medications for cardiac function), corrected QT using Bazett's (QTcB) interval <450 milliseconds (msecs).
Left ventricular ejection fraction (LVEF) >= institutional lower limit of normal
Evidence of clinically significant cardiac abnormalities, uncontrolled hypotension, left ventricular ejection fraction below the lower limit of normal for the site or experience of significant cardiac interventional procedures.
Patients with a left ventricular ejection fraction less than the institutional lower limit of normal
Known history of left ventricular ejection fraction (LVEF) ?45% or less than the institutional lower limit of normal;
Abnormal left ventricular ejection fraction (less than the lower limit of normal for a patient of that age at the treating institution or <45%)
Have major abnormalities documented by echocardiography (ECHO) with Doppler (for example, moderate or severe heart valve function defect and/or left ventricular ejection fraction <50%, evaluation based on the institutional lower limit of normal).
Ejection fraction (EF) <55% or the lower limit of normal of the institutional standard will be excluded. Only in cases where the Investigator (or the treating physician or both) suspects cardiac disease with negative effect on the EF will the EF be measured during screening using an appropriate method according to local standards to confirm eligibility (e.g., echocardiogram [ECHO], multi-gated acquisition scan [MUGA]). A historic measurement of EF no older than 6 months prior to first administration of study drug can be accepted provided that there is clinical evidence that the EF value has not worsened since this measurement in the opinion of the Investigator or of the treating physician or both.
Have a 2-dimensional (2D) echocardiogram with left ventricular ejection fraction = or > 45% in order to receive epirubicin; subjects with inadequate ejection fraction (EF) or other contraindication can proceed on study without the use of epirubicin
Have adequate cardiac function as assessed by echocardiogram, with an ejection fraction (EF) > 45%
Significant cardiovascular abnormalities as defined by any one of the following: congestive heart failure, clinically significant hypotension, symptomatic coronary artery disease, or a documented ejection fraction of < 45%; any patient with an ejection fraction (EF) of 45-49% must receive clearance by a cardiologist to be eligible for the trial
Cardiac ejection fraction (EF) < 40%
Cardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-ECHO) within 3 months of study entry (or within 1 month if received chemotherapy within the past 3 months)
Left ventricular ejection fraction (EF) >= 45%
Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrhythmias or symptomatic heart disease
Normal left ventricular ejection fraction, as defined by ejection fraction (EF) >= 50%
Adequate cardiac reserve (ejection fraction [EF] >= 50%)
Ejection fraction (EF) by multigated acquisition scan (MUGA) or 2-dimensional (2-D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more
Ejection fraction (EF) by multiple gated acquisition scan (MUGA) or 2-dimensional (D) echocardiogram within institution normal limits; in case of low EF, the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more
Patients with ECHO EF >= 45% within 28 days prior to registration
No Symptomatic Congestive Heart Failure (Ejection Fraction EF ? 50%)
Left ventricular ejection fraction (EF) >= 50%
Ejection fraction (EF) >= 50% and no uncontrolled angina, symptomatic ventricular arrhythmias, or electrocardiogram (ECG) evidence of active ischemia
Ejection fraction (EF) of < 40%, myocardial infarction (MI) within past 3 months, uncontrolled angina, severe uncontrolled ventricular arrythmias, or ECG evidence of acute ischemia.
Left ventricular ejection fraction (EF) >= 45% with no uncontrolled arrythmias or symptomatic heart disease
Ejection fraction (EF) < 35% or uncontrolled cardiac failure
Ejection fraction (EF) >= 35%
Patients with poor cardiac function defined as an ejection fraction (EF) < 40% are excluded
Left ventricular ejection fraction (EF) < 50%
Left ventricular EF > 40%.
No history of serious cardiac arrhythmia or ejection fraction (EF) < 50%
Known heart failure (ejection fraction [EF] < 40%)
Left ventricular ejection fraction (EF) < 50% at baseline
Cardiac ejection fraction (EF) >= 45% by 2-dimensional echocardiogram (2D-Echo)
Ejection fraction (EF) >= 45%
Congestive heart failure or documented cardiomyopathy with an EF ?50%, provided that EF ?35% or,
Left ventricular ejection fraction < 50%
Subject must have a left ventricular ejection fraction of ? 50%;
Left ventricular ejection fraction greater than or equal to (>=) 50 percentage (%); >=55% (cohort E only)
Left ventricular ejection fraction >= 50%
Left ventricular ejection fraction > 50%.
Left ventricular ejection fraction of < 45%
Left ventricular ejection fraction < 40%
Participant has left ventricular ejection fraction at rest ? 40%.
Subject has a documented left ventricular ejection fraction > 50%
Cardiac: left ventricular ejection fraction at rest must be ? 45%
Left ventricular ejection fraction < 40%, symptomatic coronary artery disease, or uncontrolled arrhythmias
Left ventricular ejection fraction > 50%
Left ventricular ejection fraction >= 40%.
Left ventricular ejection fraction of at least 45% by either echocardiography or radionucleotide angiography
Must have left ventricular ejection fraction > 50%
Left ventricular ejection fraction >= 50%.
Decreased cardiac function as evidenced by a left ventricular ejection fraction of < 45%
Cardiac: left ventricular ejection fraction < 35%
Left ventricular ejection fraction > 40%
Left ventricular ejection fraction > 30%
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction of > 40%.
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction >= 35%
Cardiac left ventricular ejection fraction >= 50% at rest
Left ventricular ejection fraction >= 50%
Must have left ventricular ejection fraction >= 50%
Must have left ventricular ejection fraction > 50%
Left ventricular ejection fraction >= 40%
Left ventricular ejection fraction < 50%
Left ventricular ejection fraction of at least 30% (nonmyeloablative regimen 2)
Left ventricular ejection fraction >= 40%
Adequate cardiac function with a left ventricular ejection fraction >= 40%
Adequate cardiac function with left ventricular ejection fraction >= 40%
Systolic heart failure defined as left ventricular ejection fraction =< 45%
Adequate cardiac function with left ventricular ejection fraction >= 40%
The subject has a documented left ventricular ejection fraction > 50%
Left ventricular ejection fraction ? 45%
Left ventricular ejection fraction > 45%
PART 2: Left ventricular ejection fraction > 40% OR
Patients who have other medical conditions that would contraindicate treatment with aggressive chemotherapy (including active infection, uncontrolled hypertension, congestive heart failure, unstable angina pectoris, myocardial infarction within the past 6 months, or uncontrolled arrhythmia); if the patient's cardiac history is questionable, a measurement of left ventricular ejection fraction should be obtained within 42 days prior to registration; patients with left ventricular ejection fraction < 50% are not eligible
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction at rest must be >= 35%
Left ventricular ejection fraction at least 45% on appropriate medical therapy; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricular ejection fraction >= 45%
Left ventricular ejection fraction equal or greater than 40%
Patients with symptomatic coronary artery disease, uncontrolled congestive heart failure; left ventricular ejection fraction is not required to be measured, however if it is measured, patient is excluded if ejection fraction is < 30%
Left ventricular ejection fraction greater than 40%
Left ventricular ejection fraction at rest must be >= 35%
Left ventricular ejection fraction > 50%
Left ventricular ejection fraction < 35%
Left ventricular ejection fraction >= 45%
Has Left Ventricular Ejection Fraction ? 50%
Left ventricular ejection fraction greater than 45%
Ventricular ejection fraction (VEF) =< 55% at baseline
Stable cardiac condition with a left ventricular ejection fraction of 40% or greater.
Left ventricular ejection fraction > 45%
Known history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmias
Left ventricular ejection fraction less than 50%
Left ventricular ejection fraction at rest > 40% within 3 months of registration.
Left ventricular ejection fraction >= 50% OR
Left ventricular ejection fraction >= 45%
Left ventricular ejection fraction > 40% (within 28 days of treatment start)
Left ventricular ejection fraction at rest >= 40%
Patients with a left ventricular ejection fraction of < 45%
Patients with a left ventricular ejection fraction of < 45%
Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction < 40%)
Left ventricular ejection fraction > 40% estimated
Left ventricular function 40% or greater
All subjects must have left ventricular ejection fraction ?50%.
Left ventricular ejection fraction < 45%
Left ventricular ejection fraction at rest > 40% within 3 months of registration
Participant's left ventricular ejection fraction is within normal institutional ranges
Left ventricular ejection fraction < 50%.
Left ventricular ejection fraction (LEF) >= 40%
Ventricular ejection fraction >= 40%
Left ventricular ejection fraction >= 45%
Left ventricular ejection fraction >= 50%
Left ventricular ejection fraction < 45% in patients with prior anthracycline use or otherwise at risk for left ventricular systolic dysfunction
Resting left ventricular ejection fraction <50% at the time of screening
Reduced left ventricular ejection fraction (< 50%) or other evidence of cardiac dysfunction as determined by the investigator
Left ventricular ejection fraction > 45% OR
Cardiac disease with left ventricular ejection fraction of less than 45%
Left ventricular ejection fraction at least 40%
Left ventricular ejection fraction of at least 40%
Patients with a ventricular ejection fraction (=< 30%), or respiratory compromise (FEV1 =< 40%)
Left ventricular ejection fraction < 35%
Left ventricular ejection function < 45%
Left ventricular ejection fraction < 50% by ECHO
Cardiac function - left ventricular ejection fraction >= 40%
Left ventricular ejection fraction < 35%
Patients who are receiving trastuzumab must have a left ventricular ejection fraction of >= 50%
Left ventricular ejection fraction < 50%
The patient has a left ventricular ejection fraction of < 40%
Left ventricular ejection fraction equal or greater than 40%
Patients must have left-ventricular ejection fraction > 50% at baseline
No symptoms of uncontrolled cardiac disease, left ventricular ejection fraction >= 40%
Suboptimal cardiac function as defined by decreased left ventricular ejection fraction < 55% for cohort 1, and < 50% for cohort 2
Left ventricular ejection fraction of at least 40-45%
Known history of: cardiac disease, heart failure or decreased left ventricular ejection fraction, significant clinical arrhythmias
Normal estimated left ventricular ejection fraction and no history of ischemic heart disease requiring revascularization, unless cleared by a cardiologist
Left ventricular ejection fraction >= 40%
Left ventricular ejection fraction < 50%
Left ventricular ejection fraction
Left ventricular ejection fraction < 40 %.
Baseline left ventricular ejection fraction > or = 50%
Left ventricular ejection fraction
Myocardial infarction (MI) within the previous six months, or patients with left ventricular ejection fraction of less than 45% secondary to a more remote MI.
Ventricular ejection fraction (VEF) =< 50 % at baseline
Recipient must have adequate cardiac function with a left ventricular ejection fraction > 40%.
Left ventricular ejection fraction > 50% or the institutional LLN within 28 days prior to the first dose of study treatment.
Left ventricular ejection fraction <45% or symptomatic cardiac disease, or myocardial infarction within the past 12 months
Left ventricular ejection fraction >= 40%
Left ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricular ejection fraction >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricular ejection fraction of > 40%
Subject has a left ventricular ejection fraction ?45%.
Normal cardiac function (left ventricular ejection fraction >= 50%)
Normal cardiac function (left ventricular ejection fraction >= 50%)
Left ventricular ejection fraction > 35%
Left ventricular ejection fraction > 40%
Organ dysfunction\r\n* Cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist\r\n* Pulmonary: \r\n** Diffusing capacity of the lungs for carbon monoxide (DLCO) < 40%, total lung capacity (TLC) < 40%, forced expiratory volume in the first second of breath (FEV1) < 40% and/or receiving supplementary continuous oxygen\r\n** The FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules
Organ dysfunction as defined by the following:\r\n* Symptomatic coronary artery disease or cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); if shortening fraction is < 26% a cardiology consult is required with the principal investigator (PI) having final approval of eligibility; ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease\r\n* Diffusing capacity of the lung for carbon monoxide (DLCO) < 35%, TLC < 35%, forced expiratory volume (FEV)1 < 35% and/or receiving supplementary continuous oxygen; the FHCRC PI of the study must approve of enrollment of all patients with pulmonary nodules\r\n* Liver function abnormalities: Patient with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, bridging fibrosis, and the degree of portal hypertension; the patient will be excluded if he/she is found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3mg/dL, or symptomatic biliary disease
Significant organ dysfunction that would prevent compliance with conditioning, GVHD prophylaxis, or would severely limit the probability of survival:\r\n * 1) Symptomatic coronary artery disease or ejection fraction < 35% or other cardiac failure requiring therapy (or, if unable to obtain ejection fraction, shortening fraction of < 26%); if shortening fraction is < 26% a cardiology consult is required with the principal investigator (PI) having final approval of eligibility\r\n * 2) Diffusion capacity of the lung for carbon monoxide (DLCO) < 40% total lung capacity (TLC) < 40%, forced expiratory volume in one second (FEV1) < 40% and/or receiving supplementary continuous oxygen; the Fred Hutchinson Cancer Research Center (FHCRC) study PI must approve enrollment of all patients with pulmonary nodules\r\n * 3) Liver function abnormalities: patient with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, bridging fibrosis, and the degree of portal hypertension; the patient will be excluded if he/she is found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, or symptomatic biliary disease
Shortening fraction of >= 27% or
Cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if the patient is > 50 years of age, or history of cardiac disease or anthracycline exposure; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Left ventricular ejection fraction >= 35%, or shortening fraction > 25% (for pediatric patients, a normal ejection fraction is required)
Left ventricular ejection fraction > 45% (in children, shortening fraction > 26%)
Left ventricular ejection fraction >= 40% or shortening fraction >= 25%
Participants with clinically significant arrhythmias, complex congenital heart disease, or left ventricular ejection fraction (LVEF) <50 percent (%) or shortening fraction (SF) <=28%
Left ventricular ejection fraction >= 45% or fractional shortening >= 28%
Cardiac: Shortening fraction >= 28%
Patients with impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Left ventricular ejection fraction > 45% or shortening fraction > 26%
TREATMENT WITH SJCAR19: Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
Adequate cardiac function defined as shortening fraction of ? 27% or ejection fraction ? 45%
Left ventricular ejection fraction ? 45% or fractional shortening ? 28%, and no clinically significant electrocardiogram (ECG) findings
Baseline left ventricular ejection fraction value <50% or shortening fraction of <27%
Participants with known congestive heart failure, symptomatic or Left ventricular (LV) ejection fraction <50% or shortening fraction <27% and participants with congenital long QT syndrome, bradyarrhythmias, or QT interval (QTc)>480 milliseconds on at least 2 separate electrocardiograms (ECG).
Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
PART 2 GROUP 1 INCLUSION CRITERIA: Shortening Fraction > 27%
PART 2 GROUP 2A INCLUSION CRITERIA: Shortening Fraction > 27%
PART 2 GROUP 3 INCLUSION CRITERIA: Shortening Fraction > 27%
Shortening fraction >= 28% or ejection fraction (LVEF) >= 55%, as well as
Shortening fraction >= 27% or ejection fraction >= 50%, no clinical congestive heart failure
Adequate cardiac function defined as an ejection fraction > 50% or shortening fraction >= 27%.
ECHO shortening fraction ? 27%
Shortening fraction of >= 28% or an ejection fraction >= 50%
Shortening fraction >= 27% or left ventricular ejection fraction >= 50% by echocardiogram within the past 1 year prior to registration
PART 2: Shortening fraction > 26%
Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
Left ventricular ejection fraction at rest must be >= 35%, or shortening fraction > 25%
Left ventricular ejection fraction >= 35%, or shortening fraction > 25%, unless cleared by a cardiologist
Left ventricular shortening fraction (LVSF) less than 25%
Symptomatic coronary artery disease or ejection fraction < 40% or other cardiac failure requiring therapy (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if the patient has a history of anthracyclines or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Has cardiac pathology: Participants with known congestive heart failure, symptomatic or left ventricular (LV) ejection fraction <50% or shortening fraction <27% and participants with congenital long QT syndrome, bradyarrhythmias, or QTc >480 msec on at least 2 separate electrocardiograms (ECGs).
Shortening fraction > 26%
Patients with known congestive heart failure, symptomatic or left ventricular (LV) ejection fraction < 50% or shortening fraction < 27% are not eligible
Left ventricular ejection fraction >= 40% or fractional shortening >= 28%
With impaired cardiac function as evidenced by ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Left ventricular ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Left ventricular ejection fraction >= 40% or shortening fraction >= 25%
Left ventricular ejection fraction >= 35% or shortening fraction > 25%
Left ventricular fractional shortening < 30%
Shortening fraction >= 28%
Left ventricular ejection fraction < 40% or equivalent shortening fraction < 20% in pediatric patients
Adequate cardiac function as defined as shortening fraction of > 27% OR ejection fraction of > 50%
Shortening fraction > 26%
Shortening fraction greater than or equal to 25%
Prior left chest wall irradiation or a cumulative anthracycline dose of greater or equal to 300 mg/m^2, unless the ejection fraction or fraction shortening is within normal institutional limits, in which case the patient can be enrolled
Cardiac ejection fraction < 35% (or, if unable to obtain ejection fraction, shortening fraction of < 26%); ejection fraction is required if age > 50 years or there is a history of anthracycline exposure or history of cardiac disease; patients with a shortening fraction < 26% may be enrolled if approved by a cardiologist
Pediatric patients: normal left ventricular function with ejection fraction > 55% or shortening fraction >= 27%
Adequate cardiac function defined as shortening fraction of >= 27% or ejection fraction >= 45%
Patient must have a shortening fraction ? 27% by Echo or an ejection fraction ? 50% by MUGA. Reproductive Function
Cardiac: Left ventricular ejection fraction at rest must be > 40%, or shortening fraction > 26%.
Left ventricular ejection fraction >= 45% or fractional shortening >= 28%
Left ventricular ejection fraction >= 40% or shortening fraction >= 25%
Shortening fraction greater than or equal to 25%
Adequate cardiac function defined as shortening fraction of >= 27% or ejection fraction >= 45%
Cardiac Function a. Patient must have a shortening fraction ? 29% or an ejection fraction ? 40% by ECHO/MUGA.
Left ventricular ejection fraction > 40%, or shortening fraction >= 25%
Cardiac function: left ventricular ejection fraction (LVEF) >= 40% or shortening fraction (SF) >= 25%
Left ventricular ejection fraction greater than 40%, or shortening fraction greater than or equal to 25%
Left ventricular ejection fraction >= 35% or shortening fraction > 25%, unless cleared by a cardiologist
Cardiac: left ventricular ejection fraction at rest must be greater than 40% or shortening fraction greater than 20%
Left ventricular ejection fraction >= 35% or shortening fraction > 25%
Resting ejection fraction < 50% or fractional shortening < 25%
Subjects should have a normal ejection fraction (per institutional limits), no evidence of cardiac arrhythmias requiring therapy, and a fractional shortening of > 28%
Left ventricular ejection fraction at rest must be >= 40%, or shortening fraction > 25%
Left ventricular ejection fraction < 45% and in children-shortening fraction < 26%
Left ventricular ejection fraction ? 40% or fractional shortening ? 28%
Participants with known congestive heart failure (CHF); if known, patients with left ventricular ejection fraction (LVEF) =< 40% are excluded
History of myocardial infarction =< 6 months, current symptomatic CHF or left ventricular ejection fraction (LVEF) < 40% or > grade 2 diastolic dysfunction, with no symptoms or signs of heart failure
Left ventricular ejection fraction (LVEF) ?50%. A lower LVEF (?40%) is permissible if a formal cardiologic evaluation reveals no evidence for clinically significant functional impairment, otherwise the subject may not enter the study.
Left ventricular ejection fraction (LVEF) < 45%
Participants must have a left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 45%
Participants must have a left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) < 50%, regardless of whether there are symptoms of heart failure
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
Systolic cardiac function will be assessed at screening if clinically indicated by history and physical; only patients with left ventricular ejection fraction (LVEF) >= 50% will be eligible for enrollment
Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%
Left ventricular ejection fraction (LVEF) within normal institutional limits
Left ventricular ejection fraction (LVEF) > 45%
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
Cardiac: Asymptomatic or if symptomatic, then left ventricular ejection fraction (LVEF) at rest must be >= 40% and must improve with exercise.
Known left ventricular ejection fraction (LVEF) < 40%. Patients with known coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF 40%?50% must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate
Patients who have a left ventricular ejection fraction (LVEF) < 45% at screening.
Left Ventricular Ejection Fraction (LVEF) >/=50% HER2-Expressing Breast Cancer-Specific Inclusion Criteria
Left ventricular ejection fraction (LVEF) >= 50%;
Any patient known to have an left ventricular ejection fraction (LVEF) =< 45 percent (%)
Has a left ventricular ejection fraction (LVEF) ?50% by either an ECHO or MUGA within 28 days before registration
Uncontrolled cardiac disease, or myocardial infarction within the last 12 months, or left ventricular ejection fraction (LVEF) < 50%, or QTcF interval > 470 msec
Left ventricular ejection fraction (LVEF) >= 55%
Left ventricular ejection fraction (LVEF) >= ULN (institutional limit)
Left ventricular ejection fraction (LVEF) of >= 40%
Left ventricular ejection fraction (LVEF) >= 45%
Have left ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to enrollment.
Left ventricular ejection fraction (LVEF) >= 50%
History of congestive heart failure and/or an left ventricular ejection fraction (LVEF) < 40%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) of >= 50%
Left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 40 percent (%)
Left ventricular ejection fraction (LVEF) <50% at screening.
Patients with left ventricular ejection fraction (LVEF) < 40%
Left ventricular ejection fraction (LVEF) > 40%
Left ventricular ejection fraction (LVEF) ? 50%
Left ventricular ejection fraction (LVEF) >= 45%
Adequate cardiac function with left ventricular ejection fraction (LVEF) ? 55% at baseline.
Left ventricular ejection fraction (LVEF) below 45% or lifetime exposure to anthracyclines over 350mg/m2 of daunorubicin equivalent
Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] greater than or equal to 50%)
Patients must have normal cardiac ejection fraction (left ventricular ejection fraction [LVEF] >/= 45%)
Left ventricular ejection fraction (LVEF) ? 50%
Subjects must have a left ventricular ejection fraction (LVEF) of >= 45%
LVEF (left ventricular end diastolic function) of >= 45%; LVEF between 45% and 54% must have negative stress test with increase in ejection fraction (EF) of 3-5 points with stress
Left ventricular ejection fraction (LVEF) >= 45%; LVEF assessment must have been performed within 8 weeks of enrollment
Left ventricular ejection fraction (LVEF) >= 40% on ECHO or MUGA
Left ventricular ejection fraction (LVEF) > 40%
Left ventricular ejection fraction (LVEF) >= 40%
Left Ventricular Ejection Fraction (LVEF) ? 50%.
Baseline left ventricular ejection fraction (LVEF) >= 40%
Cardiac left ventricular ejection fraction (LVEF) > 45%
Left ventricular end diastolic function (LVEF) of >= 50%
Asymptomatic or if symptomatic then left ventricular ejection function (LVEF) at rest must be >= 50% and must improve with exercise
Any patient known to have left ventricular ejection fraction (LVEF) =< 45%
Left ventricular end diastolic function (LVEF) of >= 50%
Left ventricular ejection fraction (LVEF) of >= 45%
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exercise
LVEF (left ventricular ejection fraction) >= 40%; no uncontrolled arrhythmias or symptomatic cardiac disease
Left ventricle ejection fraction (LVEF) >= 30%
Left ventricular ejection fraction (LVEF) >= 45%
Left ventricular ejection fraction (LVEF) <40%
Adequate cardiac function defined by a left ventricular ejection fraction (LVEF) ?40%, QTc <450 msec, and no evidence of clinically significant dysrhythmias on ECG
Left ventricular ejection fraction (LVEF) > 45%
Cardiac left ventricular ejection fraction (LVEF) > 45%
Patients must have a left ventricular ejection (LVEF) >= 50% within 56 days of enrollment
Left ventricular ejection fraction (LVEF) >= 40%, no uncontrolled arrhythmias or symptomatic cardiac disease.
Measurement of left ventricular ejection fraction (LVEF) should be performed in patients with prior anthracycline exposure or known history of arrhythmia or structural heart disease; in these cases, LVEF must be >= 40%
Left ventricular ejection fraction (LVEF) > 50%
Left ventricular ejection fraction (LVEF) </= 40 percent (%) at screening
Left ventricular ejection fraction (LVEF) >= 50%
Cardiac insufficiency: left ventricular ejection fraction (LVEF) < 50% or coronary artery disease requiring treatment
Cardiac ejection fraction (left ventricular ejection fraction [LVEF]) >= 50%
Left ventricle ejection fraction (LVEF) >= 55%, specimens must be collected within 10 days prior to the start of study treatment
Left ventricular ejection fraction (LVEF) >= institutional normal
Baseline left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) =< 50%
Left ventricular ejection fraction (LVEF) >= 45% corrected
Contraindication to any drug in the chemotherapy regimen, and specifically: LVEF (Left Ventricular Ejection Fraction) < 45% or peripheral neuropathy grade 2
Left ventricular ejection fraction (LVEF) < 50%;
Subject has a resting left ventricular ejection fraction (LVEF) of ? 40% obtained by echocardiography.
left ventricular ejection fraction (LVEF) of 50% or higher at baseline
LVEF at least 50%
Left ventricular ejection fraction (LVEF) >= 55%
Left ventricular ejection fraction (LVEF) > 50%
LVEF < 50%
Left ventricular ejection fraction (LVEF) < 40%
Have LVEF (left ventricular ejection fraction) <50% at screening
Left ventricular ejection fraction (LVEF) >= 50% (measured within 28 days of study entry)
Left ventricular ejection fraction (LVEF) ? 40%
Baseline left ventricular ejection fraction (LVEF) 50%.
Left ventricular ejection fraction (LVEF) >= 40%
A left ventricular ejection fraction (LVEF) must be > 50
Cardiac: left ventricular ejection fraction (LVEF) at rest ? 35% (RIC cohort) or LVEF at rest ? 40% (FIC cohort), or left ventricular shortening fraction (LVFS) ? 25%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50% for patients enrolling in the HER2 directed therapy arm
Left ventricular ejection fraction (LVEF) ?50% assessed within 28 days prior to randomization.
Left ventricular ejection fraction (LVEF) ? 40% within the 21 days prior to randomization
Left ventricular ejection fraction (LVEF) >= 50% performed no more than 4 weeks prior to enrollment
If the left ventricular ejection fraction (LVEF) < 40, patients will be excluded
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) of >= 50%
Left ventricular ejection fraction (LVEF) >= 45% if patient has known cardiac dysfunction history
Left ventricular ejection fraction (LVEF) >= 50%
Subjects must have a left ventricular ejection fraction (LVEF) of >= 45%
Normal left ventricular ejection fraction (LVEF)
REGISTRATION INCLUSION CRITERIA: Adequate cardiac function as demonstrated by left ventricular ejection fraction (LVEF) of > 55% performed no more than 4 weeks prior to randomization
Baseline left ventricular ejection fraction (LVEF) value less than (<) 55 percent (%)
Asymptomatic cardiac function or if symptomatic then left ventricular ejection fraction (LVEF) >= 50% and must improve with exercise
Uncontrolled arrhythmias or symptomatic heart disease or left ventricular ejection fraction (LVEF) < 45%
Resting left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 50%
Patients must have a left ventricular ejection fraction (LVEF) of >= 60% AND/OR
Left ventricular ejection fraction (LVEF) >/= 50% within 28 days prior to first dose of study drug administration
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 40%
The patient has an absence of coexisting medical problems that would significantly increase the risk of the chemotherapy procedure (e.g. poor left ventricular ejection fraction [LVEF<40%])
Left ventricular ejection fraction (LVEF) >= 50%
History of documented congestive heart failure (CHF) or systolic dysfunction (left ventricular ejection fraction [LVEF] < 50%)
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be >= 50% and must improve with exercise
Left ventricular ejection fraction (LVEF) of > 50% by Doppler ultrasound assessment
Patient must have a normal left ventricular ejection fraction (LVEF) (>= 53%); if a patient has a borderline LVEF (40-52%) they may be considered after consultation with cardiology and study principal investigator (PI) and treated per the guidelines
Left ventricular ejection fraction (LVEF) >= 45%
Subjects > age 60 or with clinical signs of heart disease must have ejection fraction >= 45% left ventricular ejection fraction (LVEF) pre-transplant
Left ventricular ejection fraction (LVEF) >= 40%, however, subjects with a LVEF in the range of 40-49% should have cardiology clearance prior to intervention
Participants with a history of chronic heart failure must have cardiac ECHO indicating left ventricular ejection fraction (LVEF) ? 45% within 21 days prior to first dose of study drug
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise
Left ventricular ejection fraction (LVEF) of >= 50%
Subjects who have a history of, or current evidence of uncontrolled cardiovascular disease or a left ventricular ejection fraction (LVEF) <50%
Adequate left ventricular ejection fraction (LVEF) ? 50%
Left ventricular ejection fraction (LVEF) less than 45%
Cardiac left ventricular ejection fraction (LVEF) >= 35%
Known left ventricular ejection fraction (LVEF) < 50%
Left Ventricular Ejection Fraction (LVEF) ? 50% Part 1:
Left ventricular ejection fraction (LVEF) < 50%
Left ventricular ejection fraction (LVEF) >= 50 %
LVEF
If the subject received prior anthracycline therapy, the left ventricular ejection fraction (LVEF) must be within institution's normal limits
LVEF (left ventricular ejection fraction) >= 50%
Patients with left ventricular ejection fraction (LVEF) < 45% will not be eligible
Left ventricular ejection fraction (LVEF) < 40%
Any patient known to have an left ventricular ejection fraction (LVEF) less than or equal to 45%
Any patient known to have a left ventricular ejection fraction (LVEF) less than or equal to 45%
Left ventricular ejection fraction (LVEF) ? 40%.
Left ventricular ejection fraction (LVEF) of at least 55%
Left ventricular ejection fraction (LVEF) >= 40%
Left ventricular ejection fraction (LVEF) >= 40%
Left ventricular ejection fraction (LVEF) >= 50%
LVEF of at least 50%
Left ventricular ejection fraction (LVEF) >= 50 %
Left ventricular ejection fraction (LVEF) >= 35% (within 42 days)
Cardiac: asymptomatic or if symptomatic then left ventricular ejection fraction (LVEF) at rest must be > 50% and must improve with exercise
Left ventricular ejection fraction (LVEF) >= 50%
If previously measured, left ventricular ejection fraction (LVEF) >= 50%
Left ventricular ejection fraction (LVEF) >= 45%
Left ventricular ejection fraction (LVEF) >= 40%
Left ventricular ejection fraction (LVEF) < 50%
Patients must have left ventricular ejection fraction (LVEF) > 45% or within institutional normal limits
Patients with a history of left ventricular (LV) dysfunction will be still candidates for enrollment in the study if they have documented left ventricular ejection fraction (LVEF) recovery (most recent documented LVEF of 50% or higher) for at least 6 months prior to SPECT regardless of current cardiac medication regimen
Left ventricular ejection fraction (LVEF) ? 40%
Significant cardiovascular disease including known left ventricular ejection fraction (LVEF) <40%
